Request Demo
Last update 08 May 2025
RC-148
Last update 08 May 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Action modulators |
Mechanism PD-1 modulators(Programmed cell death protein 1 modulators), VEGF modulators(Vascular endothelial growth factor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 160581189
Related
8
Clinical Trials associated with RC-148NCT06883630
A Phase Ib, Multi-Cohort, Open-Label, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of RC148 Injection as Monotherapy or Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer.
CTR20250580
RC148注射液单药或联合治疗局部晚期或转移性非小细胞肺癌的有效性及安全性多中心Ⅰb期临床研究
[Translation] A multicenter phase Ib clinical study on the efficacy and safety of RC148 injection alone or in combination in the treatment of locally advanced or metastatic non-small cell lung cancer
NCT06642545
A Randomized, Open-label, Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With RC148 Versus Albumin-bound Paclitaxone Alone or in Combination With Toripalimab in Subjects With HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
100 Clinical Results associated with RC-148
Login to view more data
100 Translational Medicine associated with RC-148
Login to view more data
100 Patents (Medical) associated with RC-148
Login to view more data
100 Deals associated with RC-148
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of Lung | Phase 2 | China | 14 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 14 Sep 2023 | |
| HER2-expressing Gastric Adenocarcinoma | Phase 2 | China | 14 Sep 2023 | |
| Ovarian Serous Tumor | Phase 2 | China | 14 Sep 2023 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | China | 14 Sep 2023 | |
| Platinum-Sensitive Primary Peritoneal Carcinoma | Phase 2 | China | 14 Sep 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 07 Sep 2023 | |
| CLDN18.2 Positive Advanced Malignant Solid Neoplasm | Phase 2 | China | 03 Aug 2023 | |
| Gastroesophageal junction adenocarcinoma | Phase 2 | China | 03 Aug 2023 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 03 Aug 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free